IS SABR COST-EFFECTIVE IN OLIGOMETASTATIC CANCER? AN ECONOMIC ANALYSIS OF SABR-COMET

Melody Qu, Yujie Chen, Gregory Zaric, Suresh Senan, Robert Olson, Stephen Harrow, Ava John-Baptiste, Stewart Gaede, Liam Mulroy, Devin Schellenberg, Sashendra Senthi, Anand Swaminath, Neil Kopek, Mitchell Liu, Andrew Warner, George Rodrigues, David Palma, Alexander Louie

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)S41-S42
JournalRadiotherapy and Oncology
Volume139
Publication statusPublished - Oct 2019

Cite this

Qu, M., Chen, Y., Zaric, G., Senan, S., Olson, R., Harrow, S., ... Louie, A. (2019). IS SABR COST-EFFECTIVE IN OLIGOMETASTATIC CANCER? AN ECONOMIC ANALYSIS OF SABR-COMET. Radiotherapy and Oncology, 139, S41-S42.